ArticleCNS neuroscience & therapeutics2026
Eye-Tracking Phenotypes Across the Depressive Spectrum: Joint Modeling of Diagnostic Group and Symptom Severity.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimsTo characterize eye-tracking alterations across the depressive spectrum and evaluate their value for diagnostic stratification and symptom severity estimation.
methodsIn this cross-sectional study, 183 participants completed a multi-paradigm eye-tracking battery. Group differences and associations with 17-item Hamilton Depression Rating Scale (HAMD-17) scores were examined with multiple-comparison correction and covariate adjustment. Classification, regression, and multi-task models used repeated nested resampling with fold-specific preprocessing.
resultsFalse discovery rate (FDR)-significant between-group differences were observed for two first-fixation latency measures from lateral-gaze orienting and for antisaccade accuracy. Among 35 candidate features, 33 had covariate-adjusted group associations at p < 0.05. Across 539 retained features, covariate-adjusted generalized additive models identified eight FDR-significant associations with HAMD-17. In multi-task analysis, Route B had numerically higher mean internal performance than Route A, although paired between-route differences were imprecisely estimated (accuracy, 0.929 vs. 0.864; macro F1, 0.928 vs. 0.859; R
conclusionEye-tracking alterations spanned the depressive spectrum and were associated with symptom severity after covariate adjustment. Between-route differences were imprecisely estimated, and joint-task training showed no clear improvement in severity estimation. External and temporal validation are required before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.